Integra LifeSciences Holdings Corporation Financial Statements (IART)
|
|
|
|
Report date
|
|
|
22.02.2023 |
31.12.2023 |
28.02.2024 |
25.02.2025 |
26.02.2026 |
|
05.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
1 558 |
1 542 |
1 542 |
1 611 |
1 635 |
|
1 645 |
|
Operating Income, bln rub |
|
|
238.9 |
111.5 |
111.5 |
28.4 |
68.3 |
|
95.3 |
|
EBITDA, bln rub |
? |
|
384.6 |
383.6 |
256.0 |
193.3 |
-326.2 |
|
-340.7 |
|
Net profit, bln rub |
? |
|
180.6 |
67.7 |
67.7 |
-6.94 |
-516.5 |
|
-495.8 |
|
|
OCF, bln rub |
? |
|
264.5 |
140.0 |
140.0 |
129.4 |
50.4 |
|
71.4 |
|
CAPEX, bln rub |
? |
|
47.1 |
66.9 |
66.9 |
104.4 |
81.4 |
|
81.6 |
|
FCF, bln rub |
? |
|
217.4 |
73.1 |
73.1 |
25.0 |
-31.1 |
|
-10.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
731.4 |
836.4 |
773.2 |
853.7 |
776.9 |
|
1 450 |
|
Cost of production, bln rub |
|
|
587.4 |
653.2 |
656.8 |
728.5 |
790.0 |
|
601.8 |
|
R&D, bln rub |
|
|
101.2 |
174.6 |
104.2 |
115.4 |
99.0 |
|
97.7 |
|
Interest expenses, bln rub |
|
|
49.6 |
51.4 |
51.4 |
70.6 |
86.3 |
|
89.9 |
|
|
Assets, bln rub |
|
|
3 890 |
3 782 |
3 782 |
4 037 |
3 602 |
|
3 578 |
|
Net Assets, bln rub |
? |
|
1 804 |
1 588 |
1 588 |
1 545 |
1 043 |
|
1 042 |
|
Debt, bln rub |
|
|
1 630 |
1 682 |
1 682 |
1 985 |
2 033 |
|
212.8 |
|
Cash, bln rub |
|
|
456.7 |
309.1 |
309.1 |
273.6 |
263.7 |
|
265.5 |
|
Net debt, bln rub |
|
|
1 173 |
1 373 |
1 373 |
1 711 |
1 769 |
|
-52.7 |
|
|
Ordinary share price, rub |
|
|
56.1 |
43.6 |
43.6 |
22.7 |
12.4 |
|
37.8 |
|
Number of ordinary shares, mln |
|
|
83.0 |
78.2 |
78.2 |
77.0 |
76.8 |
|
77.0 |
|
|
Market cap, bln rub |
|
|
4 654 |
3 404 |
3 404 |
1 747 |
953 |
|
2 909 |
|
EV, bln rub |
? |
|
5 827 |
4 777 |
4 777 |
3 458 |
2 723 |
|
2 856 |
|
Book value, bln rub |
|
|
-361 |
-535 |
-535 |
-759 |
-706 |
|
-676 |
|
|
EPS, rub |
? |
|
2.18 |
0.87 |
0.87 |
-0.09 |
-6.73 |
|
-6.44 |
|
FCF/share, rub |
|
|
2.62 |
0.94 |
0.94 |
0.32 |
-0.40 |
|
-0.13 |
|
BV/share, rub |
|
|
-4.35 |
-6.85 |
-6.85 |
-9.86 |
-9.20 |
|
-8.79 |
|
|
EBITDA margin, % |
? |
|
24.7% |
24.9% |
16.6% |
12.0% |
-19.9% |
|
-20.7% |
|
Net margin, % |
? |
|
11.6% |
4.39% |
4.39% |
-0.43% |
-31.6% |
|
-30.1% |
|
FCF yield, % |
? |
|
4.67% |
2.15% |
2.15% |
1.43% |
-3.26% |
|
-0.35% |
|
ROE, % |
? |
|
10.0% |
4.27% |
4.27% |
-0.45% |
-49.5% |
|
-47.6% |
|
ROA, % |
? |
|
4.64% |
1.79% |
1.79% |
-0.17% |
-14.3% |
|
-13.9% |
|
|
P/E |
? |
|
25.8 |
50.3 |
50.3 |
-251.5 |
-1.85 |
|
-5.87 |
|
P/FCF |
|
|
21.4 |
46.6 |
46.6 |
70.0 |
-30.7 |
|
-287.4 |
|
P/S |
? |
|
2.99 |
2.21 |
2.21 |
1.08 |
0.58 |
|
1.77 |
|
P/BV |
? |
|
-12.9 |
-6.36 |
-6.36 |
-2.30 |
-1.35 |
|
-4.30 |
|
EV/EBITDA |
? |
|
15.2 |
12.5 |
18.7 |
17.9 |
-8.35 |
|
-8.38 |
|
Debt/EBITDA |
|
|
3.05 |
3.58 |
5.36 |
8.85 |
-5.42 |
|
0.15 |
|
|
R&D/CAPEX, % |
|
|
214.9% |
261.1% |
155.8% |
110.5% |
121.5% |
|
119.8% |
|
|
CAPEX/Revenue, % |
|
|
3.02% |
4.34% |
4.34% |
6.48% |
4.98% |
|
4.96% |
|
| Integra LifeSciences Holdings Corporation shareholders |
